Serum hs-cTnT level in patients with gastric cancer after chemotherapy [9.3 (3.4–882.1) pg/mL] was increased compared with that before chemotherapy [8 (2–14) pg/mL], and the difference was statistically significant (P < 0.001) (Table 2). The gene discussed is TNNT2; the disease is gastric cancer.